Clinical Trial Update: Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial evaluating intra-arterial recombinant human tenecteplase (rhTNK-tPA) for thrombolysis in acute medium vessel occlusion due to acute isc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medium Vessel Occlusion
• Stroke

Drugs mentioned

• Intra-arterial recombinant human tenecteplase tissue-type plasminogen activator (rhTNK-tPA) (tenecteplase)

Snippet

Sponsor: Xiang Luo | Conditions: Acute Ischemic Stroke, Medium Vessel Occlusion | Phase 2, Phase 3 | Status: RECRUITING